David Sheyn, MD
Obstetrics & Gynecology · Cincinnati, OHNPI 1912131665
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,457 of the $9,986 with a category attached, or 74.7%. It is spread thinly across 16 manufacturers, the largest accounting for just 23.5%. Reporting peaked in 2023 at $2,581 and has fallen 50.2% since, to $1,284 in 2025. Among obstetrics & gynecology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 263 payments — averaging $37.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Axonics, Inc.$2K
- AbbVie$2K
- Boston Scientific$2K
- Bluewind Medical$1K
- Astellas Pharma US Inc$755
- plus $746 from 10 others
Across 72 payments — averaging $4442.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bluewind Medical$167K
- Medtronic$125K
- Axonics, Inc.$29K
What the payments were for
- Speaking & faculty fees$3333%
- Travel & lodging$1,81218%
- Food & beverage$7,45775%
- Education$3844%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 38 | $2,345 |
| Axonics, Inc. | 60 | $1,899 |
| AbbVie(2 entities) | 67 | $1,559 |
| Boston Scientific | 27 | $1,502 |
| Bluewind Medical | 5 | $1,180 |
| Astellas Pharma US Inc | 35 | $755 |
| Sumitomo Pharma America, Inc. | 15 | $460 |
| Convatec Inc. | 6 | $106 |
| Abbott | 2 | $51 |
| Myovant Sciences Inc. | 2 | $26 |
| 180 Medical, Inc. | 1 | $23 |
| Photocure Inc | 1 | $18 |
| Pfizer | 1 | $17 |
| Palette Life Sciences, Inc. | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$1,279
- REVI$1,088
- Axonics$910
- Advantage System$266
- Bulkamid$224
- GENERAL FEMALE SUI$150
- ADVANTAGE FIT$146
- GEMTESA$136
- GENERAL PELVIC ORGAN PROLAPSE$130
How this compares
$9,986 in reported general payments places this provider in the 95th percentile of 1,376 obstetrics & gynecology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 191 | $212,502 |
| MyrbetriqMirabegron | 186 | $162,561 |
| Estradiol | 354 | $23,045 |
| Methenamine Hippurate | 304 | $20,804 |
| Mirabegron ErMirabegron | 25 | $18,851 |
| VeozahFezolinetant | 28 | $17,548 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 119 | $8,462 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 392 | $7,368 |
| Colestipol Hcl | 104 | $6,058 |
| Trospium Chloride | 90 | $6,018 |
| Fosfomycin Tromethamine | 11 | $3,351 |
| Tolterodine Tartrate ErTolterodine Tartrate | 36 | $2,957 |
| Tamsulosin Hcl | 315 | $2,791 |
| Trimethoprim | 42 | $2,726 |
| Solifenacin Succinate | 81 | $2,345 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $460 | $212,502191 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $755 | $180,108214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,376 obstetrics & gynecology providers in Ohio.
Other obstetrics & gynecology in Cincinnati
- David SchwartzCincinnati$169K
- Gerard ReillyCincinnati$74K
- Michael KarramCincinnati$47K
- Sunbal JavaidCincinnati$32K
- James SosnowskiCincinnati$31K
- Gretchen FermannCincinnati$31K
- Rocco RossiCincinnati$18K
- Meredith PensakCincinnati$14K
- David DhanrajCincinnati$12K
- Samir AhujaMentor$430K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.